Day Trading Reports
  • Business
  • World News
  • Politics
  • Investing
  • Business
  • World News
  • Politics
  • Investing

Day Trading Reports

Politics

Trump’s most vulnerable nominees RFK Jr, Tulsi Gabbard get back-to-back hearings

by admin January 27, 2025
January 27, 2025
Trump’s most vulnerable nominees RFK Jr, Tulsi Gabbard get back-to-back hearings

Two of President Donald Trump’s most vulnerable administration picks will get back-to-back confirmation hearings in the Senate this week. 

Robert F. Kennedy Jr., who Trump nominated to be Secretary of Health and Human Services (HHS), and former Democratic Rep. Tulsi Gabbard, whom he selected to be Director of National Intelligence (DNI), will have committee confirmation hearings on Wednesday and Thursday. 

On Wednesday, Kennedy will have his first hearing with the Senate Finance Committee, who will eventually vote on whether to advance his nomination to the full Senate. He will have an additional hearing on Thursday with the Senate Committee on Health, Education, Labor and Pensions (HELP), but that committee will not have a vote on the nomination. 

Gabbard’s hearing with the Senate Select Committee on Intelligence will take place Thursday morning. 

The two Trump picks were some of the more controversial administration selections. Both Kennedy and Gabbard are former Democrats with histories of policy positions that clash with what many Republican senators believe. 

At issue for lawmakers on both sides is Kennedy’s history of significant criticism of vaccines and vaccination programs. For some Republicans whose states have a large farming constituency, his positions on further regulating agriculture and food production have been cause for concern. 

Gabbard’s past policy stances as they relate to national security have given bipartisan lawmakers some reason for pause, since the role she is nominated for is critical to the nation’s safety and defense. 

Both of the nominees have taken steps to moderate themselves amid the confirmation process. Kennedy has pushed back on suggestions that he is ‘anti-vaccine’ and explained, ‘If vaccines are working for somebody, I’m not going to take them away.’

‘People ought to have choice, and that choice ought to be informed by the best information,’ he said in an interview with NBC News. ‘So I’m going to make sure scientific safety studies and efficacy are out there, and people can make individual assessments about whether that product is going to be good for them.’

Gabbard recently made a remarkable reversal on a controversial intelligence tool used by the government. And her choice to change her position on the Foreign Intelligence Surveillance Act’s (FISA) section 702 managed to win her the backing of a Republican senator on the intel committee that she will need to advance out of. 

Recently asked whether her change of heart on section 702 had earned his vote, Sen. James Lankford, R-Okla., said, ‘Yeah, I am, and that was a very important piece for me.’

While both nominees have gotten some necessary Republican backing in the relevant committees, not everyone has said whether they will vote to advance the selections. And even if they are voted out of the committees, they could still face an uphill battle to be confirmed by the full Senate. 

This post appeared first on FOX NEWS

previous post
House Republicans fly down to Trump’s backyard for annual working retreat
next post
Palestinians return to devastated northern Gaza

Related Posts

Trump to sign memo lifting Biden’s last-minute collective...

February 1, 2025

Trump administration ends program to track kidnapped Ukrainian...

March 19, 2025

Supreme Court divided over state effort to defund...

April 3, 2025

Canada Elections: Prime Minister Carney’s Liberal Party to...

April 29, 2025

Trump admin seeks permission to fire head of...

February 17, 2025

Trump State Department declares Tren de Aragua, MS-13,...

February 20, 2025

Trump envoy doesn’t believe Putin wants to take...

March 24, 2025

Rubio reveals obscure Biden administration office kept ‘disinformation’...

May 1, 2025

His brother’s keeper: Gal Dalal pleads for help...

March 22, 2025

Newly surfaced report provides more clues on COVID...

April 11, 2025

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Editors’ Picks

    • 1

      Forum Energy Metals and Global Uranium Announce Exploration Update on Drill Targeting, Northwest Athabasca Project, Saskatchewan

      January 31, 2025
    • 2

      Mega M&A: Rio Tinto-Glencore Merger Sparks Chatter

      January 28, 2025
    • 3

      Excellent 90% recoveries at Cork Tree Well & Board Update

      February 17, 2025
    • 4

      Financial Agreement signed releasing $2M grant

      January 23, 2025
    • 5

      Netflix shares soar as company reports surging revenue, tops 300 million subscribers

      January 23, 2025
    • 6

      Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

      January 23, 2025
    • 7

      FDA officially authorizes Zyn nicotine pouches for sale following health review

      January 23, 2025
    • About us
    • Contacts
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: daytradingreports.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 daytradingreports.com | All Rights Reserved